8-K 15Nov2013
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
| | |
Date of Report (Date of Earliest Event Reported): | | November 15, 2013 |
Illumina, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
|
| | |
Delaware | 001-35406 | 33-0804655 |
_____________________ (State or other jurisdiction | _____________ (Commission | ______________ (I.R.S. Employer |
of incorporation) | File Number) | Identification No.) |
| | |
5200 Illumina Way, San Diego, California | | 92122 |
_________________________________ (Address of principal executive offices) | | ___________ (Zip Code) |
|
| | |
| | |
Registrant’s telephone number, including area code: | | (858) 202-4500 |
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On September 23, 2013, Illumina, Inc. (the “Company”) delivered a transfer notice to Oxford Nanopore Technologies Ltd (“Oxford Nanopore”) with respect to the Company’s intent to sell all of its shareholding in Oxford Nanopore. On November 15, 2013, the sale of the Company’s shareholding in Oxford Nanopore was completed for £56.4 million ($91.1 million) and the Company recorded a $55.2 million gain. The Company’s existing commercialization agreement with Oxford Nanopore remains in effect.
* * * * * *
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall expressly be set forth by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| | | | |
| | | | |
| | ILLUMINA, INC. |
| | | | |
Date: November 15, 2013 | | By: | | /s/ Charles E. Dadswell |
| | | | Name: Charles E. Dadswell |
| | | | Title: Senior Vice President & General Counsel |